<DOC>
	<DOCNO>NCT02324257</DOCNO>
	<brief_summary>This study first-in-human , open-label , multi-center , dose-escalation Phase 1 clinical study single-agent RO6958688 patient locally advance and/or metastatic CEA-positive solid tumor progress standard treatment , intolerant standard care ( SOC ) , and/or non-amenable SOC . The study conduct two part . Part 1 investigate safety pharmacokinetics single dose RO6958688 single patient cohort . Part 2 establish appropriate therapeutic dose ( ) base safety , pharmacokinetics , maximum tolerate dose RO6958688 weekly schedule . The anticipated time treatment maximum 24 month . The overall target sample size 90 .</brief_summary>
	<brief_title>A Study RO6958688 Patients With Locally Advanced and/or Metastatic Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Age &gt; = 18 year Locally advance and/or metastatic solid tumor patient progressed standard therapy , intolerant SOC , and/or nonamenable SOC Radiologically measurable disease accord Response Evaluation Criteria Solid Tumors ( RECIST ) version 1.1 Life expectancy ( opinion investigator ) &gt; = 12 week Eastern Cooperative Oncology Group ( ECOG ) Performance Status ( PS ) 01 All acute toxic effect prior radiotherapy , chemotherapy , surgical procedure must resolve Grade &lt; = 1 return baseline except alopecia ( grade ) Grade 2 peripheral neuropathy Adequate hematological , liver renal function Patients must agree willing use effective method contraception define protocol Locally confirm CEA expression tumor tissue ( &gt; 50 % tumor cell stain least moderate intensity ) centrally confirm CEA expression archival tumor tissue available case fresh biopsy collect Patients history clinical evidence central nervous system ( CNS ) primary tumor metastases include leptomeningeal metastasis unless previously treat , asymptomatic , requirement steroid enzymeinducing anticonvulsant last 14 day screen Patients another invasive malignancy last 2 year ( exception basal cell carcinoma tumor deem investigator low likelihood recurrence ) Evidence significant , uncontrolled concomitant disease could affect compliance protocol interpretation result contraindicate use investigational drug , include diabetes mellitus , history relevant pulmonary disorder , know autoimmune disease Uncontrolled hypertension ( systolic blood pressure [ BP ] &gt; 150 mmHg and/or diastolic BP &gt; 100 mmHg ) , unstable angina , congestive heart failure New York Heart Association classification , serious cardiac arrhythmia require treatment exception atrial fibrillation paroxysmal supraventricular tachycardia , history myocardial infarction within 6 month enrollment Active uncontrolled infection Known HIV know active hepatitis B hepatitis C infection Pregnant breastfeeding woman Known hypersensitivity component RO6958688 Concurrent therapy investigational drug Expected need regular immunosuppressive therapy Regular dose corticosteroid 28 day prior Day 1 study anticipate need corticosteroid exceed prednisone 10 mg/day equivalent within 28 day prior first RO6958688 infusion . Inhaled topical steroid permit Radiotherapy within last 28 day prior first RO6958688 infusion exception limitedfield palliative radiotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>